EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Vaccine

• Publication date

  2008-06-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2008.02.072PMID 18502003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.

  2008cited by this paper
• An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

  2008cited by this paper
• Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses

  2007cited by this paper
• Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO.Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.Lancet. 2007 Feb 24;369(9562):643-56.

  2007cited by this paper
• Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.

  2007cited by this paper
• Estimating the benefit of an HIV-1 vaccine that reduces viral load set point.

  2007cited by this paper
• An HIV vaccine--evolving concepts.

  2007cited by this paper
• Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.

  2007cited by this paper
• Randomized, Controlled Intervention Trial of Male Circumcision for Reduction of HIV Infection Risk: The ANRS 1265 Trial

  2005cited by this paper
• Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies

  2005cited by this paper
• Involvement of FcγR I (CD64) in the Mechanism of HIV-1 Inhibition by Polyclonal IgG Purified from Infected Patients in Cultured Monocyte-Derived Macrophages1

  2004cited by this paper
• Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages.

  2004cited by this paper
• Immunoglobulin G (IgG) and IgA, but also Nonantibody Factors, Account for In Vitro Neutralization of Human Immunodeficiency Virus (HIV) Type 1 Primary Isolates by Serum and Plasma of HIV-Infected Patients

  2001cited by this paper

• Understanding the performance of HIV-1 viral vector vaccines: adenovirus and poxvirus case studies

  2026cites this paper
• Use of the Highly Attenuated Vaccinia Virus, Strain NYVAC, as Recombinant Vector for Construction Vaccine Against HIV Infection

  2025cites this paper
• Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study

  2022cites this paper
• Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial

  2020cites this paper
• Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques

  2020cites this paper
• Mucosal and systemic SIV-specific cytotoxic CD4+ T cell hierarchy in protection following intranasal/intramuscular recombinant pox-viral vaccination of pigtail macaques

  2019cites this paper
• Rapid Synthetic DNA Vaccine Development for Emerging Infectious Disease Outbreaks

  2019cites this paper
• Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial

  2019cites this paper
• Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates

  2018cites this paper
• Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost

  2018cites this paper
• Non-viral Vector for Muscle-Mediated Gene Therapy

  2018cites this paper
• Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design

  2018cites this paper
• Efficient Delivery of Human Cytomegalovirus T Cell Antigens by Attenuated Sendai Virus Vectors

  2018cites this paper
• Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC

  2018cites this paper
• Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways

  2017cites this paper
• A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes

  2017cites this paper
• Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice

  2017cites this paper
• HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Prima

  2017cites this paper
• Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults

  2016cites this paper
• Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens

  2016cites this paper
• Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants

  2016cites this paper
• Streamlining Heterologous DNA-Prime and NYVAC / Protein-Boost HIV Vaccine Regimens in 1 Rhesus Macaques by Employing Improved Antigens 2 3

  2016cites this paper
• Scientific and regulatory challenges in evaluating clinical trial protocols for HIV-1/AIDS vaccines - A review from a regulatory perspective.

  2016cites this paper
• Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.

  2016cites this paper
• Searching for an hiv vaccine: a heterologous prime-boost system using replicating vaccinia virus and plant-produced virus-like particles

  2016cites this paper
• Prime-Boost Vaccination: Impact on the HIV-1 Vaccine Field

  2015cites this paper
• The Evolution of Poxvirus Vaccines

  2015cites this paper
• Title Employing Improved Antigens Allows Streamlining of Heterologous DNA-Prime and NYVAC / Protein-Boost HIV Vaccine Regimens in Rhesus Macaques Running title : Improved HIV Antigens and Delivery Schedules in Macaques

  2015cites this paper
• Comparison of the two lumpy skin disease virus vaccines, Neethling and Herbivac, and construction of a recombinant Herbivac-Rift Valley fever virus vaccine

  2015cites this paper
• Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates

  2015cites this paper
• Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines

  2014cites this paper
• HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.

  2014cites this paper
• Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial

  2014cites this paper
• Trial, Error, and Breakthrough: A Review of HIV Vaccine Development

  2014cites this paper
• Enhancing poxvirus vectors vaccine immunogenicity

  2014cites this paper
• Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives

  2014cites this paper
• Developments in HIV-1 immunotherapy and therapeutic vaccination

  2014cites this paper
• PedVacc 002: A phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi

  2014cites this paper
• Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.

  2014cites this paper
• The influence of delivery vectors on HIV vaccine efficacy

  2014cites this paper
• Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles

  2014cites this paper
• Progresses in DNA-based heterologous prime-boost immunization strategies.

  2014cites this paper
• Operator–Repressor Titration: Stable Plasmid Maintenance without Selectable Marker Genes

  2013cites this paper
• Nonhuman Primate Models for HIV/AIDS Vaccine Development

  2013cites this paper
• Novel directions in HIV-1 vaccines revealed from clinical trials.

  2013cites this paper
• The production, characterisation and application of monoclonal antibodies generated by immunisation with HIV-1C clade RGP140 envelope protein.

  2013cites this paper
• 51 – Human immunodeficiency virus vaccines

  2013cites this paper
• Marker-free plasmids for biotechnological applications - implications and perspectives.

  2013cites this paper
• IL-4 and IL-13 mediated down-regulation of CD8 expression levels can dampen anti-viral CD8⁺ T cell avidity following HIV-1 recombinant pox viral vaccination.

  2013cites this paper
• Nonreplicating vectors in HIV vaccines.

  2013influential citation
• Prospective Surveillance for Cardiac Adverse Events in Healthy Adults Receiving Modified Vaccinia Ankara Vaccines: A Systematic Review

  2013cites this paper
• Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus-HIV Subtype C Vaccine Boost in Healthy Adults

  2013cites this paper
• Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Randomised Trial in HIV-Uninfected Indian Volunteers

  2013cites this paper
• A brief history of the global effort to develop a preventive HIV vaccine.

  2013cites this paper
• Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C

  2012cites this paper
• Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C

  2012cites this paper
• Superior Induction of T Cell Responses to Conserved HIV-1 Regions by Electroporated Alphavirus Replicon DNA Compared to That with Conventional Plasmid DNA Vaccine

  2012cites this paper
• NYVAC-C in Mice of the HIV/AIDS Vaccine Candidate Improves Adaptive and Memory Responses Block Interferon Type I and II Pathways Removal of Vaccinia Virus Genes That

  2012cites this paper
• Altering an Artificial Gagpolnef Polyprotein and Mode of ENV Co-Administration Affects the Immunogenicity of a Clade C HIV DNA Vaccine

  2012cites this paper
• A vaccinia virus renaissance

  2012cites this paper
• Poxvirus vectors as HIV/AIDS vaccines in humans

  2012cites this paper
• Systems biology in the development of HIV vaccines.

  2012cites this paper
• Optimizing cellular immunity against HIV-1 Gag and preventing suppression by HIV-1 gp120

  2012cites this paper
• Removal of Vaccinia Virus Genes That Block Interferon Type I and II Pathways Improves Adaptive and Memory Responses of the HIV/AIDS Vaccine Candidate NYVAC-C in Mice

  2012cites this paper
• Improved outlook on HIV-1 prevention and vaccine development

  2012cites this paper
• “Wrapped Up” Vaccines in the Context of HIV-1 Immunotherapy

  2012cites this paper
• Gene Vaccines

  2012cites this paper
• Willingness to participate among high risk subgroups in HIV vaccine trials

  2012cites this paper
• Chapter 8 – The design of a global HIV vaccine1

  2012cites this paper
• Prime boost regimens for enhancing immunity: magnitude, quality of mucosal and systemic gene vaccines

  2012cites this paper
• Evaluation of HIV testing strategies and monitoring of immune responses in HIV-vaccinated individuals in Tanzania

  2011influential citation
• Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.

  2011cites this paper
• In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers

  2011cites this paper
• Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation.

  2011cites this paper
• MVA and NYVAC as vaccines against emergent infectious diseases and cancer.

  2011cites this paper
• Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

  2011cites this paper
• Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors

  2011cites this paper
• A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations.

  2011cites this paper
• The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens

  2011cites this paper
• Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors

  2011cites this paper
• A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses

  2011cites this paper
• A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.

  2011cites this paper
• Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).

  2011cites this paper
• The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in 1 humans triggers robust, polyfunctional and selective effector memory T cell 2

  2011cites this paper
• HIV vaccines: lessons learned and the way forward

  2010cites this paper
• Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.

  2010cites this paper
• Vaccines for Human Immunodeficiency Virus-1 Infection

  2010cites this paper
• Lessons Drawn From Recent HIV Vaccine Efficacy Trials

  2010cites this paper
• Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine

  2010cites this paper
• Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine

  2010cites this paper
• Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.

  2010cites this paper
• Title Phase I safety and immunogenicity evaluation of ADVAX , aMultigenic , DNA-based Clade C / B ' HIV-1 candidate vaccine

  2010cites this paper
• Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions

  2010cites this paper
• Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate

  2010cites this paper
• HIV vaccine could use a little help

  2010cites this paper
• Obstacles to the successful development of an efficacious T cell‐inducing HIV‐1 vaccine

  2009cites this paper
• Comparison of Human and Rhesus Macaque T-Cell Responses Elicited by Boosting with NYVAC Encoding Human Immunodeficiency Virus Type 1 Clade C Immunogens

  2009cites this paper
• Attenuated poxvirus vectors MVA and NYVAC as promising vaccine cadidates against HIV/AIDS

  2009cites this paper
• HIV-1 immune responses induced by natural infection or immunisation

  2009cites this paper
• Vaccins d’aujourd’hui et de demain : nouvelles technologies

  2009cites this paper